In patients with ESKD, the ongoing disturbance in mineral and bone metabolism leads to increased levels of fibroblast growth factor 23 (FGF-23) which has also been associated with left ventricular hypertrophy and increased troponin T levels in hemodialysis patients, suggesting a link between bone health and TnT levels [28]. This evidence concerns the gene FGF23 and left ventricular hypertrophy.